Machine Learning for Predicting and Managing Quality of Life in Lung Cancer Immunotherapy Patients

Launched by SECOND AFFILIATED HOSPITAL OF ZUNYI MEDICAL UNIVERSITY · Dec 7, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on finding better ways to understand and improve the quality of life for patients with lung cancer who are receiving immunotherapy. Researchers are using advanced computer techniques, called machine learning, to analyze patient data and identify patterns that can help predict how patients might feel during their treatment. The ultimate goal is to develop a tool that can alert doctors to changes in a patient’s well-being, allowing for timely interventions to help manage their health better.

To participate in this study, individuals must be over 18 years old, have a confirmed diagnosis of lung cancer, and currently be receiving immunotherapy. They also need to be able to communicate effectively and provide consent for their involvement. This study is not yet recruiting participants, but those who take part can expect to share their experiences and health information, which will help researchers validate the early warning model in real-world settings. Overall, this research aims to enhance patient care and support for lung cancer patients undergoing treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically diagnosed with lung cancer
• • 2. Age over 18 years
• • 3. Currently receiving immunotherapy for lung cancer
• • 4. Good verbal communication ability
• • 5. Informed consent signed by the patient or family member
• Exclusion Criteria:
• • 1. Cognitive impairment or mental illness
• • 2. Other severe diseases